[go: up one dir, main page]

KR20100113500A - 아레나바이러스 감염 치료용 항바이러스 약물 - Google Patents

아레나바이러스 감염 치료용 항바이러스 약물 Download PDF

Info

Publication number
KR20100113500A
KR20100113500A KR1020107014573A KR20107014573A KR20100113500A KR 20100113500 A KR20100113500 A KR 20100113500A KR 1020107014573 A KR1020107014573 A KR 1020107014573A KR 20107014573 A KR20107014573 A KR 20107014573A KR 20100113500 A KR20100113500 A KR 20100113500A
Authority
KR
South Korea
Prior art keywords
bibenzoimidazolyl
substituted
compound
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107014573A
Other languages
English (en)
Korean (ko)
Inventor
동쳉 다이
데니스 이. 흐루비
토브 씨. 볼켄
션 엠. 암베르크
트레비스 케이. 워렌
Original Assignee
시가 테크놀로지스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시가 테크놀로지스, 인크. filed Critical 시가 테크놀로지스, 인크.
Publication of KR20100113500A publication Critical patent/KR20100113500A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107014573A 2008-01-15 2009-01-14 아레나바이러스 감염 치료용 항바이러스 약물 Withdrawn KR20100113500A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645708P 2008-01-15 2008-01-15
US61/006,457 2008-01-15

Publications (1)

Publication Number Publication Date
KR20100113500A true KR20100113500A (ko) 2010-10-21

Family

ID=41136068

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107014573A Withdrawn KR20100113500A (ko) 2008-01-15 2009-01-14 아레나바이러스 감염 치료용 항바이러스 약물

Country Status (11)

Country Link
US (2) US8623347B2 (fr)
EP (1) EP2240023A4 (fr)
JP (1) JP5795714B2 (fr)
KR (1) KR20100113500A (fr)
CN (1) CN101990434B (fr)
AP (1) AP2010005308A0 (fr)
AU (1) AU2009232276B2 (fr)
BR (1) BRPI0905388A2 (fr)
CA (1) CA2712071A1 (fr)
WO (1) WO2009123776A2 (fr)
ZA (1) ZA201004193B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410149B2 (en) 2004-12-06 2013-04-02 Siga Technologies Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
CA2590962A1 (fr) 2004-12-06 2006-06-15 Siga Technologies, Inc. Semicarbazides de sulfonyle, semicarbazides et urees, leurs compositions pharmaceutiques et methodes pour traiter des virus a fievre hemorragique virale, y compris des infections associees a des adenavirus
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US8791110B2 (en) 2006-02-01 2014-07-29 Siga Technologies, Inc. Anti-arenaviral compounds
EP1984379A4 (fr) 2006-02-01 2011-05-18 Siga Technologies Inc Composes anti-arenaviridae
US8871746B2 (en) 2006-03-02 2014-10-28 Kineta Four, LLC Antiviral drugs for treatment of arenavirus infection
US7872037B2 (en) 2006-03-02 2011-01-18 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US7977365B2 (en) 2006-03-02 2011-07-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
JP2010528051A (ja) 2007-05-23 2010-08-19 シガ・テクノロジーズ・インコーポレーテッド デング感染症の治療または予防のための抗ウイルス薬
CA2698075C (fr) 2007-08-27 2016-04-12 Siga Technologies, Inc. Medicaments antiviraux pour le traitement d'une infection par arenavirus
JP2015193572A (ja) * 2014-03-31 2015-11-05 宇部興産株式会社 パーフルオロアルキル基を含むビベンズイミダゾール化合物、およびその製造方法
WO2016004513A1 (fr) * 2014-07-11 2016-01-14 Simon Fraser University Composés antibactériens modulateurs de la pyruvate kinase, compositions, utilisations et procédés associés
WO2016130501A1 (fr) 2015-02-09 2016-08-18 Incyte Corporation Composés aza-hétéroaryle en tant qu'inhibiteurs de pi3k-gamma
WO2017079519A1 (fr) 2015-11-06 2017-05-11 Incyte Corporation Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA54567A (fr) 2016-01-05 2021-10-27 Incyte Corp Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
PL3697789T3 (pl) 2017-10-18 2022-02-21 Incyte Corporation Skondensowane pochodne imidazolowe podstawione przez trzeciorzędowe grupy hydroksylowe, jako inhibitory pi3k-gamma
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104395D0 (en) * 1991-03-01 1991-04-17 Ici Plc Compound,preparation and use for metal extraction
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
US20070275962A1 (en) 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
CA2583694A1 (fr) * 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Formes amorphes et polymorphes de sodium telmisartan
WO2008041966A2 (fr) * 2005-08-12 2008-04-10 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Composés antibactériens à large spectre
US7977365B2 (en) * 2006-03-02 2011-07-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US7872037B2 (en) * 2006-03-02 2011-01-18 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
GB0616359D0 (en) 2006-08-16 2006-09-27 Crysoptix Ltd Organic compound,optical film and method of production thereof

Also Published As

Publication number Publication date
EP2240023A2 (fr) 2010-10-20
WO2009123776A3 (fr) 2009-12-30
US20110027227A1 (en) 2011-02-03
AU2009232276A1 (en) 2009-10-08
AP2010005308A0 (en) 2010-06-30
US8623347B2 (en) 2014-01-07
CA2712071A1 (fr) 2009-10-08
CN101990434B (zh) 2013-07-31
JP5795714B2 (ja) 2015-10-14
CN101990434A (zh) 2011-03-23
AU2009232276B2 (en) 2013-10-24
WO2009123776A2 (fr) 2009-10-08
BRPI0905388A2 (pt) 2015-10-13
ZA201004193B (en) 2011-04-28
JP2011519346A (ja) 2011-07-07
EP2240023A4 (fr) 2010-12-29
US20140100245A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
KR20100113500A (ko) 아레나바이러스 감염 치료용 항바이러스 약물
JP5380078B2 (ja) アレナウイルス感染の治療のための抗ウイルス薬剤
JP5956490B2 (ja) デングウイルス感染を治療及び予防するためのチエノピリジン誘導体類
KR101585584B1 (ko) 아레나바이러스 감염을 치료하기 위한 항바이러스 약물
TWI805952B (zh) 取代氨基丙酸酯類化合物在治療SARS-CoV-2感染中的應用
US9029376B2 (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
US8148428B2 (en) Antiviral drugs for treatment of arenavirus infection
JP2024003097A (ja) コロナウイルス感染の治療におけるファビピラビルの使用
JP2010528051A (ja) デング感染症の治療または予防のための抗ウイルス薬
JP2015517976A (ja) アレナウイルス感染症の治療のための抗ウイルス薬
JP2010526025A (ja) スルホニルセミカルバジド、カルボニルセミカルバジド、セミカルバジドおよび尿素、その薬学的組成物、ならびにアレナウイルスに関連する感染を含む、出血熱ウイルスを治療するための方法。
JP2023534752A (ja) コロナウイルス感染症の治療におけるアルテミシニン化合物の応用
CN111743899A (zh) 硝唑尼特及其活性形式替唑尼特在治疗SARS-CoV-2感染中的应用
US20230263748A1 (en) Application of benflumetol and derivatives thereof in treatment of coronavirus infection
US8791110B2 (en) Anti-arenaviral compounds
EA047956B1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
EP4419110A1 (fr) Traitement de virus à l'aide de nucléosides antiviraux
EA046990B1 (ru) Применение замещенных аминопропионатных соединений в лечении инфекции sars-cov-2
UA121022C2 (uk) Спосіб профілактики або лікування захворювань, пов'язаних зі зниженою густиною інтерферонових рецепторів

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100630

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid